Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Mehrdad Nikfarjam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4866-276X; OpenAlex author ID A5029339790. Sources: OpenAlex.

Their work

Papers
48 (first author 2, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
89
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 6 papers · 2020: 3 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 4 papers · 2025: 6 papers · 2026: 5 papers

Papers 48

  1. A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post-Resection of Pancreatic Cancer. Co-author DOI 10.1002/cam4.71535↗
  2. Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study. Co-author DOI 10.1097/ms9.0000000000004919↗
  3. Timeliness of Care and Treatment Patterns for Pancreatic Cancer in Victoria, Australia: Comparison With Optimal Care Pathways Targets. Co-author DOI 10.1111/ans.70705↗
  4. The interplay between p21-activated kinases and tumour-infiltrating dendritic cells and T cells and its implication in pancreatic cancer immunotherapy. Co-author DOI 10.1186/s12964-026-02923-y↗
  5. Thousand-And-One Kinase 3 in Pancreatic Ductal Adenocarcinoma Stemness, Microenvironment and Therapy Resistance. Last author DOI 10.3390/ijms27146290↗
  6. Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world reg… Co-author DOI 10.1186/s12889-025-23925-4↗
  7. Knockout of p21-Activated Kinase 4 Stimulates MHC I Expression of Pancreatic Cancer Cells via an Autophagy-Independent Pathway. Co-author DOI 10.3390/cancers17030511↗
  8. The Effects of PAK-Regulated Tumour Vasculature on Gemcitabine Response of Pancreatic Cancer. Co-author DOI 10.3390/cancers17213434↗
  9. Evaluation of Nanoparticle-Based Plasma Enrichment on Individuals with Primary and Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers17233765↗
  10. Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer. Co-author DOI 10.3390/cells14221806↗
  11. P-21 Kinase 1 or 4 Knockout Stimulated Anti-Tumour Immunity Against Pancreatic Cancer by Enhancing Vascular Normalisation. Co-author DOI 10.3390/ijms26178357↗
  12. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Co-author DOI 10.1016/j.esmorw.2023.100022↗
  13. Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. Co-author DOI 10.1038/s41416-024-02619-5↗
  14. Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity. Co-author DOI 10.1186/s12964-024-01670-2↗
  15. A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine. Last author DOI 10.3390/ijms252111366↗
  16. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Co-author DOI 10.1111/ajco.13807↗
  17. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response. First author DOI 10.3390/cells12232692↗
  18. CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma. Co-author PMID 37193135↗
  19. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2022.215868↗
  20. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective interna… Co-author DOI 10.1016/j.ejca.2022.06.042↗
  21. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… Co-author DOI 10.1016/j.esmoop.2021.100356↗
  22. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2021.11.005↗
  23. A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine. Last author DOI 10.1016/j.tranon.2021.101329↗
  24. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  25. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. Co-author DOI 10.1186/s13053-021-00190-1↗
  26. Correction to: Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants Co-author DOI 10.1186/s13053-021-00195-w↗
  27. Outcomes of endoscopic ultrasound as a one-off pancreatic cancer screening tool for 122 high- and moderate-risk patients. Co-author DOI 10.1002/jgh3.12432↗
  28. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Co-author DOI 10.1016/j.canlet.2019.12.020↗
  29. Cannabinoids Inhibited Pancreatic Cancer via P-21 Activated Kinase 1 Mediated Pathway. Last author DOI 10.3390/ijms21218035↗
  30. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. Co-author DOI 10.1016/j.hpb.2018.08.016↗
  31. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  32. Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer. Last author DOI 10.1089/pancan.2018.0019↗
  33. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Co-author DOI 10.1093/annonc/mdz200↗
  34. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cance… Co-author DOI 10.1152/ajpgi.00344.2018↗
  35. PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. Co-author PMID 31312349↗
  36. The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines Last author DOI 10.20944/preprints201809.0322.v1↗
  37. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. Co-author DOI 10.3748/wjg.v24.i33.3709↗
  38. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. Co-author DOI 10.3892/ijo.2017.4193↗
  39. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. Last author DOI 10.1002/ijc.30615↗
  40. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. Last author DOI 10.1186/s12885-016-2057-z↗
  41. Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. Last author DOI 10.3109/08941939.2016.1160167↗
  42. Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. Co-author DOI 10.5694/mja16.00061↗
  43. The role of p21-activated kinases in pancreatic cancer. Last author DOI 10.1097/mpa.0000000000000276↗
  44. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Co-author DOI 10.1016/j.canlet.2014.01.001↗
  45. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Last author DOI 10.1245/s10434-014-3625-6↗
  46. Improving outcomes for pancreatic cancer: radical surgery with patient-tailored, surgery-specific advanced haemodynamic monitoring. Last author DOI 10.1136/bcr-2013-008910↗
  47. Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. Co-author DOI 10.3109/08941939.2013.797057↗
  48. Concurrent lymphoma and pancreatic adenocarcinoma. Last author DOI 10.6092/1590-8577/3352↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hong Zhen He · 26 shared papers, 2013–2026 · strength 4.68
  2. Yi Ma · 8 shared papers, 2022–2026 · strength 2.33
  3. Ching‐Seng Ang · 8 shared papers, 2022–2025 · strength 2.00
  4. Arian Ansardamavandi · 4 shared papers, 2023–2025 · strength 1.15
  5. Benjamin N. J. Thomson · 7 shared papers, 2019–2026 · strength 1.10
  6. Peter Gibbs · 7 shared papers, 2019–2026 · strength 1.10
  7. Benjamin P. T. Loveday · 5 shared papers, 2024–2026 · strength 1.00
  8. Belinda Lee · 6 shared papers, 2019–2026 · strength 0.94
  9. Matthew Burge · 5 shared papers, 2019–2026 · strength 0.72
  10. Kai Wang · 6 shared papers, 2018–2020 · strength 0.68
  11. Sam Banks · 3 shared papers, 2024–2026 · strength 0.60
  12. Adnan M. Nagrial · 4 shared papers, 2019–2024 · strength 0.48
  13. Adrian M. Fox · 3 shared papers, 2023–2024 · strength 0.45
  14. Hong He · 1 shared paper, 2026 · strength 0.43
  15. Rui Jian · 1 shared paper, 2026 · strength 0.43
  16. James Tai · 1 shared paper, 2026 · strength 0.43
  17. Dannel Yeo · 6 shared papers, 2013–2017 · strength 0.38
  18. Marios Efthymiou · 3 shared papers, 2020–2021 · strength 0.35
  19. Rhys Vaughan · 3 shared papers, 2020–2021 · strength 0.35
  20. Shehara Ramyalini Mendis · 2 shared papers, 2024–2025 · strength 0.35
  21. Marion Harris · 3 shared papers, 2019–2023 · strength 0.33
  22. Yat Hang To · 2 shared papers, 2024 · strength 0.32
  23. Daniel Gerald Croagh · 3 shared papers, 2019–2022 · strength 0.31
  24. David Wai-Meng Tai · 2 shared papers, 2019–2026 · strength 0.30
  25. Kai Wang · 2 shared papers, 2018–2023 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.